Literature DB >> 23612880

The magnetic resonance imaging 'rule of five': predicting the occurrence of relapse.

Charity J Morgan1, Ashutosh Ranjan, Inmaculada B Aban, Gary R Cutter.   

Abstract

BACKGROUND: Clinical intuition suggests that a sharp increase in the number of enhancing lesions should signal an increased risk of relapse. The 'rule of five' recommends that subjects exhibiting at least five lesions over the baseline level be referred for closer monitoring. This rule has been used as an informal safety criterion with limited formal evaluation.
OBJECTIVE: The purpose of this study was to determine the best threshold for the rule and to demonstrate its predictive validity for risk of subsequent relapses for multiple sclerosis (MS) trials.
METHODS: We used logistic regression modeling to apply the rule to patient data from a phase II clinical trial. Predictive validity was ascertained using rate ratios and receiver operating characteristic (ROC) curves.
RESULTS: We found that, for these data, a threshold of five lesions over the baseline constituted the best definition of a threshold. Overall, 35% of subjects broke the rule at least once. Breaking the rule increased the odds of imminent relapse by a factor of 3.2 (95% confidence interval (CI): 1.8-5.5).
CONCLUSION: Breaking the rule of five was found to be a significant predictor of an imminent relapse. Length of follow-up and the number of lesions discovered via magnetic resonance imaging (MRI) were also significant predictors of relapse.

Entities:  

Keywords:  Multiple sclerosis; logistic regression; magnetic resonance imaging scans; relapsing–remitting; safety monitoring

Mesh:

Year:  2013        PMID: 23612880      PMCID: PMC4128343          DOI: 10.1177/1352458513485147

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  5 in total

Review 1.  Key issues in the diagnosis and treatment of multiple sclerosis. An overview.

Authors:  Paul O'Connor
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

2.  Placebo-controlled trial of oral laquinimod for multiple sclerosis.

Authors:  Giancarlo Comi; Douglas Jeffery; Ludwig Kappos; Xavier Montalban; Alexey Boyko; Maria A Rocca; Massimo Filippi
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

3.  Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses.

Authors:  J Petkau; S C Reingold; U Held; G R Cutter; T R Fleming; M D Hughes; D H Miller; H F McFarland; J S Wolinsky
Journal:  Mult Scler       Date:  2008-06-05       Impact factor: 6.312

4.  Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.

Authors:  M P Sormani; D K Li; P Bruzzi; B Stubinski; P Cornelisse; S Rocak; N De Stefano
Journal:  Neurology       Date:  2011-10-05       Impact factor: 9.910

5.  Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis.

Authors:  C A Riddell; Y Zhao; D K B Li; A J Petkau; A Riddehough; G R Cutter; A Traboulsee
Journal:  Neurology       Date:  2011-11-16       Impact factor: 9.910

  5 in total
  5 in total

1.  T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis.

Authors:  Cather M Cala; Carson E Moseley; Chad Steele; Sarah M Dowdy; Gary R Cutter; Jayne M Ness; Tara M DeSilva
Journal:  J Neuroimmunol       Date:  2016-04-30       Impact factor: 3.478

2.  Visual imaging as a predictor of neurodegeneration in experimental autoimmune demyelination and multiple sclerosis.

Authors:  Gabrielle M Mey; Kirsten S Evonuk; McKenzie K Chappell; Laura M Wolfe; Rupesh Singh; Julia C Batoki; Minzhong Yu; Neal S Peachey; Bela Anand-Apte; Robert Bermel; Daniel Ontaneda; Kunio Nakamura; Kedar R Mahajan; Tara M DeSilva
Journal:  Acta Neuropathol Commun       Date:  2022-06-15       Impact factor: 7.578

3.  Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.

Authors:  David H Miller; Robert J Fox; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Claudia A M Wheeler-Kingshott; Daniel J Tozer; David G MacManus; Tarek A Yousry; Mary Goodsell; Minhua Yang; Ray Zhang; Vissia Viglietta; Katherine T Dawson
Journal:  Neurology       Date:  2015-02-13       Impact factor: 9.910

4.  Personalized activity index, a new safety monitoring tool for multiple sclerosis clinical trials.

Authors:  Yinshan Zhao; Yumi Kondo; Anthony Traboulsee; David Kb Li; Andrew Riddehough; A John Petkau
Journal:  Mult Scler J Exp Transl Clin       Date:  2015-04-24

5.  The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives.

Authors:  Rehana Z Hussain; Peter V Sguigna; Annette Okai; Crystal Wright; Mariam Madinawala; Ann D Bass; Gary R Cutter; Navid Manouchehri; Olaf Stuve
Journal:  J Cent Nerv Syst Dis       Date:  2022-08-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.